CStone Pharmaceuticals (02616.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.39

From 52W high−54.79%

Volume15.63M

Market capHKD 7.41B

P/E (TTM)—

P/S (TTM)15.0x

Div yield—

Key dataSep 18, 2026

Open

HKD 5.39

From 52W high

−54.79%

Volume

15.63M

Market cap

HKD 7.41B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−14.9x

P/E (TTM)

—

RSI (14)

43.1

MomentumView details →

1D Return

−0.84%

YTD Return

+1.23%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−14.9x

EV/Sales

12.1x

P/S (TTM)

15.0x

P/B (TTM)

4.9x

ProfitabilityView details →

Gross Margin

55.49%

Net Margin

−98.40%

EBITDA Margin

−81.30%

ROE (TTM)

−32.16%

ROA (TTM)

−20.22%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

+137.62%

EPS YoY

−46.90%

FCF YoY

+87.63%

Revenue CAGR 3Y

−17.57%

EPS CAGR 3Y

—

EBITDA YoY

−58.53%

MomentumView details →

1D Return

−0.84%

YTD Return

+1.23%

1Y Return

−37.24%

RSI (14)

43.1

vs 50D SMA

−0.12%

vs 200D SMA

−14.86%

Capital & dividendView details →

Debt/Equity

0.28x

Current Ratio

3.58x

Quick Ratio

3.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.20

EPS Surprise

10.53%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.54

Avg Surprise (4Q)

10.53%

Rev Surprise

49.59%

Financials snapshotView financials →

Revenue (TTM)

600.17M

Net Income (TTM)

−657.62M

Op. CF (TTM)

−508.89M

Next earningsApr 1, 2027 →

Latest newsMore news →

CStone Pharmaceuticals reported interim results for the six months ended June 2026, with revenue of RMB 205 million, up 315% year-on-year, and a narrowed net loss of RMB 252 million.24d ago

CStone Pharmaceuticals repurchased 4.597 million shares in the open market last month, all intended for cancellation.60d ago

Similar companies

Ionis Pharmaceuticals, Inc.IONS Alphamab Oncology09966.HK CARsgen Therapeutics Holdings Limited02171.HK Alkermes plcALKS 苑东生物688513.SH Immunovant, Inc.IMVT Find similar companies →

Latest newsMore news →

CStone Pharmaceuticals reported interim results for the six months ended June 2026, with revenue of RMB 205 million, up 315% year-on-year, and a narrowed net loss of RMB 252 million.24d ago CStone Pharmaceuticals repurchased 4.597 million shares in the open market last month, all intended for cancellation.60d ago